Logo
04.01.2019

Article

Bristol-Myers Squibb to Acquire Celgene for $ 74 Billion

Bristol-Myers Squibb and Celgene announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $ 74 billion. The combination creates a leading special...

read...